Rocuronium pharmacokinetics

Matteo RS, Ornstein E, Schwartz AE, Ostapkovich N, Stone JG. Pharmacokinetics and pharmacodynamics of rocuronium (Org 9426) in elderly surgical patients. Anesth Analg 1993 77(6) 1193-7. 

Cooper RA, Maddineni VR, Mirakhur RK, Wierda JM, Brady M, Fitzpatrick KT. Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. Br J Anaesth 1993 71(2) 222-6. 

Szenohradszky J, Fisher DM, Segredo V, Caldwell JE, Bragg P, Sharma ML, Gruenke LD, Miller RD. Pharmacokinetics of rocuronium bromide (ORG 9426) in patients with normal renal function or patients undergoing cadaver renal transplantation. Anesthesiology 1992 77(5) 899-904. 

Khalil M, D Honneur G, Duvaldestin P, Slavov V, De Hys C, Gomeni R. Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. Anesthesiology 1994 80(6) 1241-7. 

Rocuronium (Fig. 16.21) preserves the vecuronium trend of tertiary versus quaternary nitrogens, but with further modifications on the nitrogen substitutes. The dmg has a similar pharmacokinetic, duration of action, and toxicity profile to vecuronium but six times less potent. It has a fast onset of action (about 2 minutes). Recuronium is supplied as its bromide salt in multiple-dose vials containing volumes of 50 or 100 mL at a concentration of 10 mg/mL. 

---